IL6 and COVID-19: Although systemic corticosteroid and interleukin-6 (IL-6) blockade had been shown to be clinically effective in lowering the mortality of patients with severe-to-critical COVID-19 (5, 6), their uses may be associated with adverse effect such as immunosuppression and secondary infection.